Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that long-term administration of tamsulosin hydrochloride 0.2 mg is effective, safe, and well-tolerated for improving symptoms and quality of life in patients with LUTS of BPH.

This study developed and validated three analytical techniques for the simultaneous quantification of Finasteride and Tamsulosin Hydrochloride in pharmaceutical dosage forms, with proven accuracy and precision.

Man stopped medications due to sexual side effects, found relief with prostatic artery embolisation.

Patients follow treatment well, but many change medicines; good information helps compliance.

This study developed a simple HPLC method for accurately estimating tamsulosin and finasteride in pharmaceutical forms, demonstrating good precision and potential application in combined dosage analysis.

This study developed a precise and simple HPLC method for estimating tamsulosin and finasteride simultaneously in pharmaceutical forms, demonstrating good precision and potential usefulness for combined dosage analysis.

This study developed and validated a liquid chromatography-mass spectrometry method for accurately identifying and quantifying tamsulosin and finasteride in pharmaceutical forms, showing its effectiveness for quality control.

This study found that combining tamsulosin and finasteride significantly improved urinary symptoms and IPSS scores in elderly patients with benign prostatic hyperplasia compared to finasteride alone, with good safety profiles.

This research discusses a validated HPTLC method for simultaneously determining Tamsulosin Hydrochloride and Finasteride in bulk and pharmaceutical dosage forms but reports no new clinical results.

This study suggests that the use of tamsulosin may worsen sleep-disordered breathing in some patients with obstructive sleep apnea being treated with CPAP.

This study reports an increase in the use of tamsulosin/finasteride for benign prostatic syndrome in Germany but highlights that reliable comparisons with monotherapies are lacking due to study design deficiencies.

The researchers reported that they successfully developed and validated RP-HPLC and TLC methods for accurately measuring tamsulosin hydrochloride and finasteride in combination forms.

5α-reductase inhibitors may cause persistent sexual dysfunction and depression, needing more research on long-term effects.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

This study concluded that alpha(1)-adrenoceptor antagonists are more effective than finasteride in the short term for reducing symptoms of lower urinary tract symptoms associated with benign prostatic hyperplasia.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This study concluded that men with benign prostatic hyperplasia receiving steroid 5α-reductase inhibitors, such as dutasteride or finasteride, have a higher risk of developing new onset type 2 diabetes compared to those taking tamsulosin.

This study found that tamsulosin, finasteride use, and aging are significantly associated with increased risk of intraoperative floppy iris syndrome during cataract surgery, while doxazosin does not appear to pose this risk.

This study found that current use of benzodiazepines, α1-blockers (like tamsulosin, alfuzosin, terazosin), finasteride, and possibly rivastigmine is associated with increased risk of intraoperative floppy iris syndrome in cataract surgery patients.

This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

This review discusses hormonal control and treatment options for benign prostatic hyperplasia, highlighting similar efficacy and safety between finasteride and dutasteride, and reports no clinical results; further studies are suggested for new therapeutic agents.

This paper reviews the role of pharmacokinetic/pharmacodynamic modeling in drug development, emphasizing its application for drug dosing guidance, safety resolution, and therapeutic monitoring improvement, without presenting new clinical results.

This study found that the herbal combination PRO 160/120 significantly improved nocturnal voiding frequency in patients with moderate-to-severe LUTS/BPH compared to placebo, with similar effectiveness to tamsulosin and finasteride.

This study found that combining 4 mg doxazosin with 0.2 mg tamsulosin improved urinary symptoms with fewer vasodilatory side effects compared to a higher dose of doxazosin in hypertensive males with LUTS.

Doxazosin and finasteride negatively affect sexual function in men with BPH.